Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xenetic Biosciences Q2 EPS $(0.83) Misses $(0.15) Estimate, Sales $726.40K Beat $570.00K Estimate

Author: Benzinga Newsdesk | August 14, 2024 09:41am
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.15) by 453.33 percent. This is a 20.29 percent decrease over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $726.40 thousand which beat the analyst consensus estimate of $570.00 thousand by 27.44 percent. This is a 11.58 percent increase over sales of $651.00 thousand the same period last year.

Posted In: XBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist